Summary Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products.The company’s lead product candidate comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnascan, Fluorochol, AAACholine, Cholscan, MIBITEC, Adamibi, Leukokit, Neurolite and Lumark.
AAA develops new medicines which targets the orphan diseases in the field of cardiology, oncology, neurology and inflammation.It is also engaged in manufacturing Positron Emission tomography (PET) and single-photon emission computed tomography (SPECT).
The company operates in France, Italy, the UK, Germany, Switzerland, Spain, Poland, Portugal, Israel, the US, and Canada, among others. AAA is headquartered in Saint-Genis-Pouilly, Auvergne, France.
Advanced Accelerator Applications SA - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
The global Micropump market is expected to reach US$ 5,172.86 million in 2028 from as estimated value of US$ 1,553.01 million in 2021. The market is likely to grow with a CAGR of 18.8% from 2021-2028. The growth of the market is due to increasing demand for micropumps in medical device industry, and improved accuracy compared to traditional...
The global particle size analysis market reached a value of US$ 351.7 Million in 2020. Looking forward, the analyst expects the market to exhibit moderate growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different...
Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective This report provides you with a landscape description and analysis of prodrug antibodies and cytokines employing conventional and novel masking technology...
175 pages •
By The Business Research Company
• Sep 2021
Major players in the remdesivir market are Gilead Sciences, Inc., Bright Gene, Hainan Haiyao, Kelun Pharma, Hunan Warrant Pharmaceutical, Cipla, Pfizer, Merck, Cayman Chemical, and Dr. Reddy’s Laboratories. The global remdesivir market is expected to grow from $1.98 billion in 2020 to $2.55 billion in 2021 at a compound annual growth...
The global single-use bioreactors market is projected to reach USD 8.8 billion by 2026 from USD 3.4 billion in 2021, at a CAGR of 21.1% during the forecast period. Increasing adoption of SUBs among small companies and startups, reduced automation complexity, ease in the cultivation of marine organisms, reduced energy and water consumption,...
The industrial agitator market is expected to grow from US$ 1,931.76 million in 2021 to US$ 2,638.61 million by 2028; it is estimated to grow at a CAGR of 4.0% during 2021-2028. The industrial agitator market is widely used in food and beverages, paint, and coatings, chemical, mineral, pharmaceutical, cosmetics, paper & pulp, water...
Executive Summary Global Hexamethyldisilazane Market was valued at USD 202.32 Million and xx Kilotonne by volume in the year 2020. Hexamethyldisilane (HMDS) is an organosilicon compound used as a reagent or precursor to bases and is primarily used as a silylating agent in the process of manufacturing pharmaceutical drugs...
U.S. Restricted Access Barrier System Market Size, Share & Trends Analysis Report By Application (Pharmaceutical, Chemical Manufacturing, Medical), And Segment Forecasts, 2020 - 2028 U.S. Restricted Access Barrier System Market Growth & Trends The U.S. restricted access barrier system market...
Deblistering Machines: Market Size From $116.92 million in 2020, the global Deblistering Machines market is projected to reach $174.06 million by 2028. Based on our analysis the market is expected to grow at a CAGR of 5.1% from 2020 - 2028 timeframe. Some of the prominent trends that the market is witnessing...
The healthcare analytical testing services market is projected to reach USD 9.8 billion by 2026 from USD 5.6 billion in 2021, at a CAGR of 11.9%. Growth in the market is driven by the rising trend of outsourcing of analytical testing by pharmaceutical companies and medical device companies, an increasing number of clinical trials, and the...
Pharmaceutical R&D Expenditure
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.